Contrasting Dare Bioscience (DARE) and Its Rivals
Dare Bioscience (NASDAQ: DARE) is one of 290 public companies in the “Bio Therapeutic Drugs” industry, but how does it compare to its competitors? We will compare Dare Bioscience to related companies based on the strength of its risk, institutional ownership, valuation, earnings, dividends, analyst recommendations and profitability.
Valuation & Earnings
This table compares Dare Bioscience and its competitors revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|Dare Bioscience||$760,000.00||-$39.30 million||N/A|
|Dare Bioscience Competitors||$290.27 million||$35.99 million||59.92|
Volatility & Risk
Dare Bioscience has a beta of 2.45, suggesting that its share price is 145% more volatile than the S&P 500. Comparatively, Dare Bioscience’s competitors have a beta of 5.82, suggesting that their average share price is 482% more volatile than the S&P 500.
This table compares Dare Bioscience and its competitors’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Dare Bioscience Competitors||-5,375.04%||-161.60%||-36.20%|
Insider and Institutional Ownership
8.1% of Dare Bioscience shares are held by institutional investors. Comparatively, 49.6% of shares of all “Bio Therapeutic Drugs” companies are held by institutional investors. 28.6% of Dare Bioscience shares are held by company insiders. Comparatively, 16.9% of shares of all “Bio Therapeutic Drugs” companies are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
This is a breakdown of current recommendations for Dare Bioscience and its competitors, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Dare Bioscience Competitors||1133||3431||11934||241||2.67|
As a group, “Bio Therapeutic Drugs” companies have a potential upside of 39.59%. Given Dare Bioscience’s competitors higher possible upside, analysts plainly believe Dare Bioscience has less favorable growth aspects than its competitors.
Dare Bioscience competitors beat Dare Bioscience on 7 of the 9 factors compared.
Dare Bioscience Company Profile
Dare Bioscience, Inc., formerly Cerulean Pharma Inc., is a healthcare company. The Company is focused on the development and commercialization of products in women’s reproductive health. Its lead product candidate is Ovaprene, a clinical stage, non-hormonal contraceptive ring. The Company is developing Ovaprene to provide protection over multiple weeks of use and require no intervention at the time of intercourse. Ovaprene has a custom intravaginal ring design, with a permeable mesh in the center of the ring that creates a partial barrier to sperm, and a mechanism to release locally acting spermiostatic agents through the ring. The combination of these two complementary approaches produces attractive contraceptive efficacy outcomes that are consistent with the effective barrier option, the diaphragm, and short-acting hormonal options, such as oral pill, patches and vaginal ring.
Receive News & Ratings for Dare Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dare Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.